Oppenheimer reiterated an Outperform rating and $5.50 price target on Geron Corporation (NASDAQ: GERN) following the publication of two articles in the New England Journal of Medicine (NEJM). The article highlight the company's flagship compound imetelstat for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).

Analyst Ling Wang commented, "Yesterday after market close, GERN announced the publication of two articles in the New England Journal of Medicine (NEJM) for its flagship compound imetelstat for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF), respectively. The key efficacy and safety data are essentially the same as prior presentations. New exploratory mutational/molecular analysis in MF were also published in an effort to explore potential correlations between mutational status and response to imetelstat. In our view, imetelstat’s unique ability to potentially address the underlying cause of the hematologic malignancies (the malignant progenitor cells clones in the bone marrow) should differentiate it sufficiently from available therapies and offer paradigmchanging potential in a variety of hematologic malignancies with significant unmet medical needs."

For an analyst ratings summary and ratings history on Geron Corporation click here. For more ratings news on Geron Corporation click here.

Shares of Geron Corporation closed at $3.05 yesterday.